The real world utilization of MRD in myeloma across Europe

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the real-world utilization of measurable residual disease (MRD) in myeloma across Europe. He highlights MRD's role in defining high-quality complete remissions (CRs) and notes that the PERSEUS trial (NCT03710603) used MRD to guide treatment decisions. If these treatments are approved in Europe, MRD monitoring should become standard practice as it was in the trial. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.